Page 9 - Project Orbis News Today

Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery - News - PharmaTimes

Takeda UK Ltd. is pleased to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to EXKIVITY (mobocertinib) in Great Britain as a monotherapy treatment for adult patients with epidermal growth factor receptor (EGFR) Exon 20 insertion ...

NHS deal with manufacturer Takeda, makes England the first in Europe to have the game changing drug.

The agency brokered a deal between NICE and Takeda, under which the sponsor will provide the drug on a budget-neutral basis while NICE completes its appraisal.

A new drug targeting a rare kind of lung cancer could give patients two extra years of life after NHS drug watchdogs approving it for use. About 100 patients in England will benefit per year.

Dr. Ross Soo, Senior Consultant at Department of Haematology-Oncology (NUS, Singapore) explicates advances in Lung cancer treatment through immunotherapy and the development of more effective targeted therapies

New technologies could enable medicine to progress in leaps and bounds, but only with the right regulatory and ethical frameworks.

A reflection by Dr June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency

One in two people will develop cancer in their lifetime. In fact, such is the impact of this devastating disease on the NHS that cancer is named as

Surveys undertaken with global pharma in 2018 and 2021 show an impressive turnaround of opinion on the attractiveness of the UK for research and medicines launches over the past three years. Angela McFarlane interprets the results - Magazine Article - PharmaTimes